Title and Organization:
Kevin Judice currently serves as chief executive officer of DiCE Molecules. Prior to this he founded K2 Therapeutics and was CEO and Chief Scientific Officer of Achaogen, Inc., a biopharmaceutical company that he co-founded to develop novel antibiotics for the treatment of life-threatening infections. In addition to setting corporate strategy and building the leadership team as President and CEO, Kevin also served as the company's Chief Scientific Officer. In this role, he was responsible for the overall scientific strategy, research priorities, and portfolio management. Along with its commercial efforts, Achaogen is engaged in several collaborations with the federal government to develop bio-terrorism countermeasures. Previously, Kevin held positions of increasing responsibility at Genentech and Theravance. As one of the first ten employees at Theravance, he played a key role in defining the company's scientific strategies and led the team that discovered telavancin, a new antibiotic for the treatment of multidrug-resistant "superbugs". Kevin graduated magna cum laude with a BS in Chemistry from Texas A&M University. Following that, he received his Ph.D. in Organic Chemistry from UCLA and was an NIH postdoctoral fellow at UC Berkeley. He is an author and inventor on over two dozen scientific papers and patents. Kevin is a member of the 2008 class of Henry Crown Fellows at the Aspen Institute and a member of the Aspen Global Leadership Network.